Abstract
Introduction
This study investigated the role of homocysteine thiolactone (HcyT) in the development of macrovascular complications in Chinese patients with type 2 diabetes. HcyT has been proposed as a possible molecular basis for homocysteine (Hcy)-induced vascular damage.
Methods
One hundred and sixty subjects were recruited into this study: 40 healthy controls and 120 patients with type 2 diabetes. Plasma Hcy levels were measured by polarization immunoassay and HcyT concentrations were monitored using high-performance liquid chromatography on a reversephase C18 column with ultraviolet detection. Plasma folic acid and vitamin B12 levels were measured using radioimmunoassay methods.
Results
Plasma Hcy and HcyT concentrations in patients with type 2 diabetes were significantly higher than in healthy controls (Hcy [25th and 75th quartiles]: 9.28 [7.51–11.82] vs. 5.64 [5.17–8.00] μmol/L, P=0.01; HcyT: 3.38 [2.94–4.73] vs. 2.91 [2.77–3.08] nmol/L, P<0.05). Plasma Hcy and HcyT levels in patients with macrovasculopathy (MAVP) were significantly higher compared with patients without MAVP (Hcy: 10.36 [7.67–12.45] vs. 7.85 [6.76–10.52] μmol/L, P<0.05; HcyT: 4.27 [3.02–5.11] vs. 3.12 [2.63–3.77] nmol/L, P<0.05). Plasma HcyT concentrations were positively correlated with urinary excretion of albumin/creatinine (Alb/Cr; r=0.285, P=0.007), duration of diabetes (r=0.249, P=0.019), age (r=0.233, P=0.028), and fibrinogen levels (r=0.289, P=0.034). Plasma HcyT concentrations were negatively correlated with high-density lipoprotein levels (r=−0.223, P=0.037). Binary logistic regression showed that HcyT, Hcy, smoking, serum triglyceride, and urine Alb/Cr were significantly associated with the risk of diabetic MAVP (P<0.05).
Conclusion
Hcy and HcyT levels were associated with the development and progression of diabetic MAVP. HcyT may provide a plausible chemical mechanism for explaining Hcy toxicity in the human vascular endothelium.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Jacobsen DW. Homocysteine and vitamin in cardiovascular disease. Clin Chem. 1998;44:1833–1843.
Boushey CJ, Beresford SAA, Omenn GS, Otulsky MAG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057.
Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem. 2003;36:431–441.
Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures: possible mechanism for pathological consequences of elevated homocysteine level. J Biol Chem. 1997;272:1935–1942.
Jakubowski H. The molecular basis of homocysteine thiolactone-mediated vascular disease. Clin Chem Lab Med. 2007;45:1704–1716.
Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 1999;13:2277–2283.
Canadian Diabetes Association. 2003 Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2003;27:1–163.
Lanfredini M, Fiorina P, Peca MG, et al. Fasting and post-methionine load homocysteine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin dependent diabetes mellitus patients. Metabolism. 1998;47:915–921.
Smulders YM, Rakic M, Slaats EH, et al. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care. 1999;22:125–132.
Jakubowski H. The determination of homocysteine-thiolactone in biological samples. Anal Biochem. 2002,308:112–119.
Jakubowski H, Goldman E. Editing of errors in amino acids selection for protein synthesis. Microbiol Rev. 1992;56:412–429.
Jakubowski H. Translational accuracy of aminoacyl-tRNA synthetases: implications for atherosclerosis. J Nutr. 2001;131(suppl.):2983–2987.
Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia: vascular injury and arterial thrombosis. N Engl J Med. 1974;291:537–543.
Mercie P, Garnier O, Lascoste L, et al. Homocysteine-thiolactone induces caspaseindependent vascular endothelial cell death with apoptotic features. Apoptosis. 2000;5:403–411.
Jakubowski H, Fersht AR. Alternative pathways of editing noncognate amino acids by aminoacyl-tRNA synthetases. Nucleic Acids Res. 1981;9:3105–3117.
Ferretti G, Bacchetti T, Marotti E, Curatola G. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. Metabolism. 2003;52:146–151.
Ferguson E, Parthasarathy S, Joseph J, Kalyanaraman B. Generation and initial characterization of a novel polyclonal antibody directed against homocysteine thiolactone-modified low density lipoprotein. J Lipid Res. 1998;39:925–933.
Yang X, Gao Y, Zhou J, et al, Plasma homocysteine thiolactone adducts associated with risk of coronary heart disease. Clin Chim Acta. 2006;364:230–234.
Daneshvar P, Yazdanpanah M, Cuthbert C, Cole DE. Quantitative assay of plasma homocysteine thiolactone by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom. 2003;17:358–362.
Chwatko G, Jakubowski H. Urinary excretion of homocysteine-thiolactone in humans. Clin Chem. 2005;51:408–415.
Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res. 2000;87:45–51.
Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase: a protective mechanism against protein N-homocysteinylation. J Biol Chem. 2000;275:3957–3962.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gu, W., Lu, J., Yang, G. et al. Plasma homocysteine thiolactone associated with risk of macrovasculopathy in Chinese patients with type 2 diabetes mellitus. Adv Therapy 25, 914–924 (2008). https://doi.org/10.1007/s12325-008-0097-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-008-0097-8